Capstone Investment Advisors
NKTR icon

Capstone Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Capstone Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-120
Closed -$32K – 1353
2020
Q1 		$32K Sell
120
-2,327
-95% -$720K ﹤0.01% 1092
2019
Q4 		$792K Buy
2,447
+187
+8% +$54.2K ﹤0.01% 1050
2019
Q3 		$617K Buy
2,260
+207
+10% +$75.9K ﹤0.01% 1044
2019
Q2 		$1.1M Buy
2,053
+126
+7% +$63.2K 0.01% 912
2019
Q1 		$971K Buy
1,927
+480
+33% +$284K 0.01% 822
2018
Q4 		$713K Buy
1,447
+260
+22% +$157K 0.01% 729
2018
Q3 		$1.08M Buy
+1,187
New +$1.01M 0.01% 574

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Capstone Investment Advisors's NKTR Position: Q2 2020 in Review

Capstone Investment Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 121 shares — an estimated $32K sold.

Capstone Investment Advisors first reported a position in NKTR in Q4 2017 and held it in 8 quarters. The position peaked at $860K in Q4 2019. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

  • Capstone Investment Advisors reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Capstone Investment Advisors sold 121 Nektar Therapeutics shares in Q2 2020, an estimated $32K.
  • Capstone Investment Advisors first reported a position in Nektar Therapeutics in Q4 2017 and held it in 8 quarters.
  • Capstone Investment Advisors's Nektar Therapeutics position peaked at $860K in Q4 2019.
  • 260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on Capstone Investment Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.